{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-034175","form_type":"8-K","ticker":null,"cik":"0001463361","company_name":"Unity Biotechnology, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.246440+00:00","generated_at":"2026-06-04T11:27:46.687394+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Unity Biotechnology restates financials for warrant misclassification; net loss overstated by $15.5M in 2022","bullets":["Audit committee determined warrants issued Aug 2022 should be liabilities, not equity; all affected periods are being restated.","Previously reported cash, equivalents and marketable securities balances unaffected; cash runway into Q3 2025 unchanged.","Preliminary cumulative effect: understatement of other income and overstatement of net loss by $15.5M for FY2022, $2.3M for nine months ended Sep 2023.","Company expects at least one material weakness in internal control over financial reporting; controls deemed ineffective for restated periods.","Restated financials will be included in 2023 10-K; prior financials for non-reliance periods should no longer be relied upon."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-034175","json":"https://secwatch.observer/filing/0000950170-24-034175.json","markdown":"https://secwatch.observer/filing/0000950170-24-034175.md","text":"https://secwatch.observer/filing/0000950170-24-034175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024034175/0000950170-24-034175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024034175/ubx-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:27:46.687394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bc2ad57d7204f75af85ca5060e5f863a5b8d53e","claim":"Unity Biotechnology, Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"As a result, the audited and unaudited financial statements for each of the Non-Reliance Periods should no longer be relied on.","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024034175/0000950170-24-034175-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}